DLPIC
NBIX icon

Davide Leone & Partners Investment Company’s Neurocrine Biosciences NBIX Stock Holding History

Davide Leone & Partners Investment Company’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-26,091
Closed -$2.54M – 93
2021
Q1 		$2.54M Buy
26,091
+7,688
+42% +$806K 0.32% 31
2020
Q4 		$1.76M Buy
+18,403
New +$1.78M 0.18% 43

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
DCP
DSM Capital Partners Palm Beach Gardens, Florida $5.84B AUM 22.63% 1-Year Est. Return

Davide Leone & Partners Investment Company's NBIX Position: Q2 2021 in Review

Davide Leone & Partners Investment Company sold out of Neurocrine Biosciences (NBIX) in Q2 2021, closing a stake of 26,091 shares — an estimated $2.54M sold.

Davide Leone & Partners Investment Company first reported a position in NBIX in Q4 2020 and held it in 2 quarters. The position peaked at $2.54M in Q1 2021. 409 funds tracked by Wall St. Rank hold NBIX as of Q2 2021.

  • Davide Leone & Partners Investment Company reported no remaining Neurocrine Biosciences position as of Q2 2021 after selling out during the quarter.
  • Davide Leone & Partners Investment Company sold 26,091 Neurocrine Biosciences shares in Q2 2021, an estimated $2.54M.
  • Davide Leone & Partners Investment Company first reported a position in Neurocrine Biosciences in Q4 2020 and held it in 2 quarters.
  • Davide Leone & Partners Investment Company's Neurocrine Biosciences position peaked at $2.54M in Q1 2021.
  • 409 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2021.

Based on Davide Leone & Partners Investment Company's 13F filing for Q2 2021, filed 16 Aug 2021.